Fundraising FoxAmygdala Neurosciences
San Francisco, US · Founded 2015 · Delaware corporation · 1 known investors
Find your way into Amygdala Neurosciences
Sign up to see every warm intro you have to Amygdala Neurosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amygdala Neurosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amygdala Neurosciences is a biopharmaceutical company developing oral medications to treat alcohol and substance use disorders by targeting the ALDH2 enzyme. The company addresses unmet clinical needs in addiction treatment through novel pharmacotherapies.
Founders & leadership
AM
Adrienne M. MacMillanExecutive
IF
Ivan F. DiamondNamed on SEC filing
Board
LG
MC
Mack C. Mitchell, Jr.Board director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7M disclosed across 2 rounds · 2015–2019
▶$5.6MraisedNov 2019 · 39 investors · Other Health CareRule 506(b)
▶$5.6MraisedNov 2019 · 39 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter M. StrumphExecutive Officer, Director
- Ivan F. DiamondDirector
- Howard JaffeDirector
- Louis G. LangeDirector
- William F. LeeDirector
- Adrienne M MacMillanExecutive Officer
- Mack C. Mitchell, Jr.Director
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.4MraisedApr 2015 · 25 investors · Other Health CareRule 506(b)
▶$1.4MraisedApr 2015 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Louis G. LangeDirector
- Mack C. Mitchell, Jr.Director
- Adrienne M. MacMillanExecutive Officer
- Ivan F. DiamondExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Amygdala Neurosciences do?
- Amygdala Neurosciences is a biopharmaceutical company developing oral medications to treat alcohol and substance use disorders by targeting the ALDH2 enzyme. The company addresses unmet clinical needs in addiction treatment through novel pharmacotherapies.
- Who are Amygdala Neurosciences's investors?
- Amygdala Neurosciences's investors include Asset Management Company.
- How much funding has Amygdala Neurosciences raised?
- Amygdala Neurosciences has disclosed $7M raised across 2 rounds.
- Where is Amygdala Neurosciences headquartered?
- Amygdala Neurosciences is headquartered in San Francisco, US.